Medi­gene spins out AAV tech to a new biotech up­start in Swe­den

Ger­many’s Medi­gene AG is get­ting a new biotech start­up go­ing, out-li­cens­ing its AAV-like par­ti­cle tech to the new­ly mint­ed Swedish biotech com­pa­ny 2A Phar­ma AB, lo­cat­ed in Malmö, Swe­den.

Medi­gene says that it was work­ing on AAV par­ti­cle tech be­fore de­vot­ing it­self to T cells and im­munother­a­py. And now 2A Phar­ma plans to use it to de­vel­op new vac­cines, for can­cer as well as in­fec­tious dis­eases. And the up­start says it’s raised enough cash to take the biotech up to the clin­ic, though it did not spell out the de­tails on that score.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.